Scancell Holdings (SCLP)

 

SCLP Share PerformanceMore

52 week high29.800 28/08/15
52 week low12.000 02/12/15
52 week change -9.750 (-34.82%)
4 week volume3,575,352 27/06/16

Media for (SCLP)

Presenter: Dr Richard Goodfellow
31/07/2015
Presenter: Dr Richard Goodfellow
02/06/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Eurogentec manufacturing agreement

RNS Number: 7970E Scancell Holdings Plc 21 July 2016 21 July 2016 Scancell Holdings Plc ("Scancell" or the "Company") Leading DNA plasmid manufacturer Eurogentec appointed to manufacture new SCIB1 material Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, today announces an agreeme...

Scancell extends Ichor commercial option

Scancell Holdings has been granted a further extension to its option to licence the commercial use of Ichor Medical System...

Extension to Ichor Commercial Option

RNS Number: 6714E Scancell Holdings Plc 20 July 2016 20 July 2016 Scancell Holdings Plc ("Scancell" or the "Company") Extension to Ichor Commercial Option Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer is pleased to announce that it has been granted a further extension to its option to licenc...

Peer-reviewed publication on Moditope? platform

RNS Number: 0030E Scancell Holdings Plc 13 July 2016 Scancell Holdings Plc ("Scancell" or the "Company") Peer-reviewed publication highlights advantages of Moditope technology platform Potential to develop completely new class of immuno-oncology therapeutics Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the tr...

Scancell notes SCIB1 compelling survival data

Scancell Holdings said SCIB1 continues to deliver compelling survival data in patients with resected Stage III/IV melanoma.

SCIB1 compelling survival data in melanoma

RNS Number: 3373D Scancell Holdings Plc 06 July 2016 6 July 2016 Scancell Holdings Plc ("Scancell" or the "Company") SCIB1 continues to deliver compelling survival data in melanoma Scancell to present update at the Oxford Technology VCT AGM and Proactive Investors One2One Forum Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel im...

Second Price Monitoring Extn

RNS Number: 7027C Scancell Holdings Plc 29 June 2016 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this security would still have executed more than a pre-determined perc...

Price Monitoring Extension

RNS Number: 7011C Scancell Holdings Plc 29 June 2016 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's auction call before the execution oc...

Fundamental DataMore

EPS-1.07
Dividend yield0 %

Latest discussion posts More

Users' HoldingsMore

Users who hold Scancell Holdings also hold..
LLOYDS GRP.21%
SIRIUS MINERALS13%
BARCLAYS11%
PREMAITHA11%
TESCO10%

Codes & Symbols

ISINGB00B63D3314
SymbolsSCLP, LSE:SCLP, SCLP.L, SCLP:LN, LON:SCLP, XLON:SCLP